A multicenter, controlled, prospective endpoint trial confirmed that routinely taking blood pressure (BP)-lowering medications at bedtime, as opposed to upon waking, resulted in improved ambulatory BP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and markedly reduced major cardiovascular disease (CVD) events. The trial included 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) assigned (1:1) to take the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory BP monitoring was performed for 48 h. During a 6.3-year median follow-up, 1752 patients experienced the primary CVD outcome. Adjusted for significant influential characteristics, patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio of the primary CVD outcome (0.55) and each of its single components, i.e. CVD death (0.44), myocardial infarction (0.66), coronary revascularization (0.60), heart failure (0.58), and stroke (0.51). The bedtime treatment was at least as safe, and with similar patient compliance and adherence, as usual upon-waking treatment. The findings are consistent with previous studies. Source: https://academic.oup.com/eurheartj/
Higher nighttime light exposure was associated with adverse changes in cardiac structure and function and…
In two UK cohorts including 977,282 adults, drinking beverages at a “very hot” temperature was…
In a UK prospective cohort of 502,188 adults followed for a median of 13.6 years,…
Regular smoking was associated with a lower risk of Parkinson disease (PD), and among people…
Alcohol-attributable cancer deaths in the USA doubled from 11,361 in 1990 to 23,126 in 2023,…
A systematic review and meta-analysis found that the prevalence of unruptured intracranial aneurysms (UIAs) is…
This website uses cookies.